宁波美诺华药业股份有限公司

Group 1 - The company held its 16th meeting of the 5th Board of Directors on August 26, 2025, with all 5 directors present, complying with relevant laws and regulations [3][4][6] - The meeting approved the 2025 semi-annual report and its summary, which will be disclosed on the Shanghai Stock Exchange [4][7] - The meeting also approved a special report on the storage and actual use of raised funds for the first half of 2025, which will be disclosed on the Shanghai Stock Exchange [7][8] Group 2 - The Board approved a proposal to abolish the Supervisory Board and amend the Articles of Association, transferring the powers of the Supervisory Board to the Audit Committee of the Board [9][10] - This proposal requires approval from the shareholders' meeting [11][27] - The Board also approved the revision and formulation of certain management systems, with some requiring shareholder approval [12][14] Group 3 - The company announced the date and details for the 2025 First Extraordinary General Meeting of Shareholders, scheduled for September 11, 2025 [31][33] - The meeting will adopt a combination of on-site and online voting methods [33][34] - Shareholders must register to attend the meeting, with specific registration details provided [39][40] Group 4 - The company reported on the actual use of raised funds, indicating that the total amount raised from the issuance of convertible bonds was approximately RMB 520 million, with a net amount of about RMB 512.7 million after expenses [45][46] - As of June 30, 2025, the company has implemented various projects funded by these raised funds, including a project for the production of pharmaceutical raw materials [49][50] - The company has established a management system for raised funds, ensuring compliance with relevant regulations [46][47]